A new study suggests that a non-invasive urine biomarker could help identify people who are at higher risk of developing cancer years before they show symptoms. Researchers report that urine-based molecular measurements can predict cancer risk over a five-year period, using a structured approach that turns biomarker readings into a risk score.
The work is based on analysis of 24-hour urine samples from participants in the Lifelines population cohort in the Netherlands. The study compares individuals who later developed cancer with a larger control group who did not, then scales findings to estimate risk across a broader adult population. The researchers used mass spectrometry to measure specific chondroitin sulphate disaccharides and combined them into a “GAGome score,” evaluating it alone and alongside 13 established risk factors.
Coverage differs mainly in emphasis. PravdaReport highlights the potential public-health relevance for India’s cancer burden and describes the technical measurement and scoring strategy in more detail. Times of India leads more directly with the potential relevance for flagging cancer risk in India, while the provided summary does not add further methodological specifics.
